A new blood-based assay was shown to detect minimal residual disaes in patients with stage 0 to stage 3 breast cancer with a 100-fold greater sensitivity compared with digital droplet polmerase chain reaction, according to results published online with Clinical Cancer Research. 

“Our goal is to be able to turn patients who would have developed metastatic disease into patients who won’t,” stated co-first author Heather Parsons, a medical oncologist at Dana-Farber Cancer Institute and associated scientist at the Broad Institute of Massachusetts Institute of Technology. “In the future, if we can find those patients with residual cancer early enough, determine whether they would benefit from another course of therapy, and give them an effective additional treatment, we could potentially change the course of their disease.”

To read more, visit AJMC.

Tags: